Clinical trial NCT01021670: An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride
Official title: A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY or Alternate Care
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sexual Dysfunction, Physiological
Ejaculation
Keywords: Dapoxetine hydrochloride
Priligy
Premature ejaculation
Non-dapoxetine hydrochloride treatment(s)
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2009-11-30
Enrollment: 10027
Sex: MALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men diagnosed with premature ejaculation will be enrolled in the study by participating health care providers in clinical practice settings.

Brief summary: The purpose of the study is to collect information regarding the safety of dapoxetine hydrochloride when used in clinical practice to treat men with premature ejaculation. Dapoxetine hydrochloride is a selective inhibitor of serotonin reuptake that is indicated for the treatment of patients with premature ejaculation.

Detailed description: This is a 12-week, observational study to collect and evaluate safety data for dapoxetine hydrochloride and alternate care/non-dapoxetine hydrochloride treatment(s) defined as any treatment (eg, oral, topical, or behavioral) other than dapoxetine hydrochloride, which have been recommended and prescribed for men who have a diagnosis of premature ejaculation. The primary objective of the study is to describe the safety profile of dapoxetine hydrochloride when used in clinical practice. The safety of dapoxetine hydrochloride will be assessed duing the study by monitoring the occurrence of all adverse events experienced by patients including adverse events of special interest (eg, syncope, characterized as loss of consciousness). Safety will also be assessed by monitoring patient use of all concomitant medications/treatments including prescription medications, over the counter medications, vitamins and herbal supplements, and other types of therapies such as electrical stimulation, acupuncture, special diets, and exercise regimens. Approximately 12,000 men with premature ejaculation will be enrolled in the study of which approximately 6,000 patients will be treated with dapoxetine hydrochloride. All patients who present to the practice for an evaluation of premature ejaculation, or who have a diagnosis of premature ejaculation and are currently being treated will be considered for enrollment in the study. All treatment decisions will be made at the discretion of the participating health care provider. The study will consist of 3 periods: a pre-observational (screening/baseline) period (Visit 1), an 12-week observational period (Visits 2, 3, and 4), and a 4-week post-observational period. At Visit 1, the health care provider will make or confirm the diagnosis of premature ejaculation and determine if treatment with dapoxetine hydrochloride or alternate care/non-dapoxetine hydrochloride is appropriate for the patient. There will be no study-specific selection criteria other than the guidance provided by the Summary of Product Characteristics for dapoxetine hydrochloride as it is intended that the participating health care provider will use the Summary of Product Characteristics for dapoxetine hydrochloride as a guide to identify appropriate patients for the study, and the types of patients who should use caution or avoid using dapoxetine hydrochloride. If the healthcare provider determines that the patient is a candidate for the study, he/she will explain the details of the study to the patient. Patients who are interested in participating in the study should be willing and able to be treated with dapoxetine hydrochloride and to continue to participate in the study as long as dapoxetine hydrochloride continues to be administered for the duration of the 12-week observational period, even in those situations where topical and/or behavioral alternate care treatments are added to the dapoxetine hydrochloride treatment regimen. Patients who wish to participate in the study will be asked to sign and date an informed consent to allow the health care provider to collect information required for the study. At Visit 1, a signed informed consent form will be obtained from the patient and information will be collected including demographics (for example, the patient's race and age), medical history including premature ejaculation history, physical examination findings, and orthostatic vital sign (blood pressure and heart rate/pulse) measurements. If the health care provider determines that the patient should be treated with dapoxetine hydrochloride, the health care provider will instruct the patient on the administration of dapoxetine hydrochloride according to the dosage and administration guidelines in the Summary of Product Characteristics for dapoxetine hydrochloride as follows: the recommended starting dose of dapoxetine hydrochloride is 30 mg, taken with or without food with at least one full glass of water approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed. If the effect of dapoxetin hydrochloride at a dose of 30 mg is insufficient and the side effects are acceptable, the dose may be increased to the maximum recommended dose of 60 mg. If the health care provider determines that the patient should be treated with alternate care/non-dapoxetine hydrochloride treatment(s), the health care provider will instruct the patient on the administration of those treatments as prescribed or directed. Following Visit 1, all patients will participate in a 12-week observational period where they will return for up to 3 study visits (Visits 2, 3, and 4) according to the health care provider's local practice. At each visit, the health care provider will evaluate if the dose of dapoxetine hydrochloride or alternate care/non-dapoxetine hydrochloride treatment(s) needs to be increased or decreased and information regarding the occurrence of adverse events and the use of concomitant medications/treatment will be collected. Approximately 4 weeks following the end of the 12-week observational period or the patient's last visit in the study, the health care provider will contact the patient by telephone to assess the occurrence of any adverse events experienced by the patient and the use of any concomitant medications or treatments taken since the last study visit. Additional telephone contact with the patient may be performed by the health care provider to obtain additional information to determine the patient's safety or survival status. Regardless of the patient's status at the end of the study (ie, completed, discontinued treatment, withdrew early), patients who receive dapoxetine hydrochloride will be asked to complete a survey to provide feedback to the healthcare provider on the whether or not the dapoxetine hydrochloride Patient Brochure and/or Patient Information Leaflet was useful and informative. Patients may only participate in the study one time. Patients who receive dapoxetine hydrochloride in the study should not be enrolled again to receive alternate care/non-dapoxetine hydrochloride treatment(s) upon study completion or discontinuation of dapoxetine hydrochloride). The recommended starting dose of dapoxetine hydrochloride is 30 mg, taken with or without food with at least 1 full glass of water approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed. Patients will take dapoxetine hydrochloride for 12 weeks during the observational period of the study. Alternate care/non dapoxetine hydrochloride treatment(s) will be administered to patients in accordance with the prescribing information and/or directions for use.

Eligibility criteria: Inclusion Criteria:

* In accordance with the therapeutic indication stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be candidates for enrollment if they have an intravaginal ejaculatory latency time of less than two minutes
* Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes
* Marked personal distress or interpersonal difficulty as a consequence of premature ejaculation
* Poor control over ejaculation

Exclusion Criteria:

* In accordance with the contraindications, special warnings and precautions for use as stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be excluded from treatment if they have hypersensitivity to dapoxetine hydrochloride or to any of the excipients
* Significant pathological cardiac conditions such as: heart failure (New York Heart Association \[NYHA\] class II-IV), conduction abnormalities (second or third degree atrioventicular (AV) block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease, or significant valvular disease
* Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI
* Concomitant treatment with thioridazine, concomitant treatment with serotonin reuptake inhibitors (selective serotonin reuptake inhibitors \[SSRIs\], serotonin-norepinephrine reuptake inhibitors \[SNRIs\], tricyclic antidepressants \[TCAs)\] or other medicinal/herbal products with serotonergic effects (for example, L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)
* Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc.
* Moderate and severe hepatic impairment

Primary outcomes:
measure: The primary outcome measure is safety. Safety will be assessed by monitoring the occurrence of adverse events and the use of concomitant medications or therapies during the study.
timeFrame: Safety will be assessed at Visit 1 through 4 during the 12 week observation period and up to approximately 4 weeks after the End-of-Observation/Early Withdrawal Visit.
Secondary outcomes:
Other outcomes:
Locations:
city: Karpfenberg
country: Austria
city: Reutte
country: Austria
city: Vienna
country: Austria
city: Helsinki
country: Finland
city: Kouvola
country: Finland
city: Mikkeli
country: Finland
city: Oulu
country: Finland
city: Turku
country: Finland
city: Ahlen
country: Germany
city: Ahrensburg
country: Germany
city: Apolda
country: Germany
city: Bad Doberan
country: Germany
city: Bad Schönborn
country: Germany
city: Bamberg
country: Germany
city: Bautzen
country: Germany
city: Berlin
country: Germany
city: Bonn
country: Germany
city: Braunschweig
country: Germany
city: Bremen
country: Germany
city: Bruchsal
country: Germany
city: Böblingen
country: Germany
city: Castrop-Rauxel
country: Germany
city: Celle
country: Germany
city: Chemnitz
country: Germany
city: Dachau
country: Germany
city: Dessau
country: Germany
city: Dorsten
country: Germany
city: Dortmund
country: Germany
city: Dossenheim
country: Germany
city: Dresden
country: Germany
city: Duisburg
country: Germany
city: Düren
country: Germany
city: Düsseldorf
country: Germany
city: Eisenberg
country: Germany
city: Erfurt
country: Germany
city: Erlangen
country: Germany
city: Essen
country: Germany
city: Frankfurt
country: Germany
city: Garmisch-Partenkirchen
country: Germany
city: Gotha
country: Germany
city: Grimma
country: Germany
city: Grünstadt
country: Germany
city: Göppingen
country: Germany
city: Hagenow
country: Germany
city: Halle
country: Germany
city: Hamburg
country: Germany
city: Hannover
country: Germany
city: Heidelberg
country: Germany
city: Heilbronn
country: Germany
city: Hemmoor
country: Germany
city: Herford
country: Germany
city: Herten
country: Germany
city: Herzogenaurach
country: Germany
city: Hochheim
country: Germany
city: Höchberg
country: Germany
city: Jena
country: Germany
city: Kaiserslautern
country: Germany
city: Karlsruhe
country: Germany
city: Kempten
country: Germany
city: Kiel
country: Germany
city: Kirchheim
country: Germany
city: Kleinmachnow
country: Germany
city: Krefeld
country: Germany
city: Kronach
country: Germany
city: Köln
country: Germany
city: Lampertheim
country: Germany
city: Landsberg
country: Germany
city: Leipzig
country: Germany
city: Leverkusen
country: Germany
city: Lichtenfels
country: Germany
city: Lutherstadt Eisleben
country: Germany
city: Lüdinghausen
country: Germany
city: Magdeburg
country: Germany
city: Markkleeberg
country: Germany
city: Mülheim
country: Germany
city: München
country: Germany
city: Münster
country: Germany
city: Neckargemünd
country: Germany
city: Neu-Ulm
country: Germany
city: Neumünster
country: Germany
city: Neuss
country: Germany
city: Nordhausen
country: Germany
city: Nürnberg
country: Germany
city: Oberursel
country: Germany
city: Oranienburg
country: Germany
city: Osnabrück
country: Germany
city: Ostfildern
country: Germany
city: Peine
country: Germany
city: Planegg
country: Germany
city: Plauen
country: Germany
city: Radebeul
country: Germany
city: Rastatt
country: Germany
city: Remscheid
country: Germany
city: Reutlingen
country: Germany
city: Rinteln
country: Germany
city: Rostock
country: Germany
city: Rottenberg
country: Germany
city: Rottweil
country: Germany
city: Sangerhausen
country: Germany
city: Schleswig
country: Germany
city: Schriesheim
country: Germany
city: Schwerin
country: Germany
city: Senftenberg
country: Germany
city: Sindelfingen
country: Germany
city: Speyer
country: Germany
city: Stadthagen
country: Germany
city: Starnberg
country: Germany
city: Strausberg
country: Germany
city: Stuttgart
country: Germany
city: Sömmerda
country: Germany
city: Taucha
country: Germany
city: Ulm
country: Germany
city: Unterschleißheim
country: Germany
city: Velbert
country: Germany
city: Villingen-Schwenningen
country: Germany
city: Wiesbaden
country: Germany
city: Wiesloch
country: Germany
city: Wolfenbüttel
country: Germany
city: Wolfsburg
country: Germany
city: Wuppertal
country: Germany
city: Zwickau
country: Germany
city: Aveiro
country: Portugal
city: Braga
country: Portugal
city: Castelo Viegas N/A
country: Portugal
city: Estoril
country: Portugal
city: Lisboa
country: Portugal
city: Matosinhos N/A
country: Portugal
city: P-1100 Lisboa N/A
country: Portugal
city: Portimão
country: Portugal
city: Póvoa Do Varzim
country: Portugal
city: Santo Tirso
country: Portugal
city: Alcorcon
country: Spain
city: Alginet
country: Spain
city: Alicante
country: Spain
city: Almeria
country: Spain
city: Aravaca
country: Spain
city: Aviles
country: Spain
city: Badalona
country: Spain
city: Barakaldo
country: Spain
city: Barcelona N/A
country: Spain
city: Barcelona
country: Spain
city: Burgos
country: Spain
city: Cadiz
country: Spain
city: Calatayud
country: Spain
city: Calella
country: Spain
city: Castellon
country: Spain
city: Ciudad Real
country: Spain
city: Cordoba
country: Spain
city: Cullera
country: Spain
city: Cádiz
country: Spain
city: El Prat De Llobregat
country: Spain
city: Gandia
country: Spain
city: Girona
country: Spain
city: Granada
country: Spain
city: Ibiza
country: Spain
city: Jaen
country: Spain
city: L'Hospitalet De Llobregat
country: Spain
city: La Coruña
country: Spain
city: La Laguna
country: Spain
city: Las Palmas De Gran Canaria
country: Spain
city: Leon
country: Spain
city: Llanera
country: Spain
city: Lleida
country: Spain
city: Logroño
country: Spain
city: Los Boliches
country: Spain
city: Lugo
country: Spain
city: Madrid
country: Spain
city: Malaga
country: Spain
city: Manacor
country: Spain
city: Marbella
country: Spain
city: Mataro
country: Spain
city: Murcia
country: Spain
city: Málaga
country: Spain
city: Ontiyent
country: Spain
city: Orense
country: Spain
city: Oviedo
country: Spain
city: Palamos
country: Spain
city: Palma De Mallorca
country: Spain
city: Pamplona
country: Spain
city: Parla
country: Spain
city: Pontevedra
country: Spain
city: Port De Bollenca
country: Spain
city: Requena
country: Spain
city: Ribeira
country: Spain
city: Rota
country: Spain
city: Sabadell
country: Spain
city: Salamanca
country: Spain
city: San Juan De Alicante
country: Spain
city: San Sebastian De Los Reyes
country: Spain
city: San Sebastian
country: Spain
city: Sanlucar De Barrameda
country: Spain
city: Santa Cruz De Tenerife
country: Spain
city: Santander
country: Spain
city: Santiago De Compostela
country: Spain
city: Sevilla
country: Spain
city: Silla
country: Spain
city: Tarragona
country: Spain
city: Terrassa
country: Spain
city: Toledo
country: Spain
city: Utrera
country: Spain
city: Valencia
country: Spain
city: Valladolid
country: Spain
city: Vigo
country: Spain
city: Vilanova I La Geltru
country: Spain
city: Villamayor
country: Spain
city: Xátiva
country: Spain
city: Zaragoza
country: Spain
city: Billdal
country: Sweden
city: Eskilstuna
country: Sweden
city: Göteborg
country: Sweden
city: Karlshamn
country: Sweden
city: Luleå
country: Sweden
city: Lund
country: Sweden
city: Motala
country: Sweden
city: Stockholm
country: Sweden
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC C. Clinical Trial
role: STUDY_DIRECTOR
References: